Dr. Rony Abou-Jawde, MD

Claim this profile

Mosaic Life Care

Studies Colorectal Cancer
Studies Cancer
3 reported clinical trials
7 drugs studied

Area of expertise

1Colorectal Cancer
Rony Abou-Jawde, MD has run 2 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
GNAQ positive
2Cancer
Rony Abou-Jawde, MD has run 1 trial for Cancer. Some of their research focus areas include:
BRAF positive

Affiliated Hospitals

Image of trial facility.
Mosaic Life Care
Image of trial facility.
Heartland Regional Medical Center

Clinical Trials Rony Abou-Jawde, MD is currently running

Image of trial facility.

IDE196 Combinations

for Solid Tumors

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.
Recruiting1 award Phase 1 & 29 criteria
Image of trial facility.

FORE8394

for Cancer

The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.
Recruiting1 award Phase 2

More about Rony Abou-Jawde, MD

Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Rony Abou-Jawde, MD has experience with
  • FORE8394
  • IDE196
  • Binimetinib
  • Crizotinib
  • RGX-202-01
  • FOLFIRI

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rony Abou-Jawde, MD specialize in?
Rony Abou-Jawde, MD focuses on Colorectal Cancer and Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Rony Abou-Jawde, MD currently recruiting for clinical trials?
Yes, Rony Abou-Jawde, MD is currently recruiting for 3 clinical trials in Saint Joseph Missouri. If you're interested in participating, you should apply.
Are there any treatments that Rony Abou-Jawde, MD has studied deeply?
Yes, Rony Abou-Jawde, MD has studied treatments such as FORE8394, IDE196, Binimetinib.
What is the best way to schedule an appointment with Rony Abou-Jawde, MD?
Apply for one of the trials that Rony Abou-Jawde, MD is conducting.
What is the office address of Rony Abou-Jawde, MD?
The office of Rony Abou-Jawde, MD is located at: Mosaic Life Care, Saint Joseph, Missouri 64507 United States. This is the address for their practice at the Mosaic Life Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.